Terremoto Biosciences raised $108 million in a Series C to advance small-molecule drug programs targeting AKT. The company said funding supports first-in-human testing for its next-generation chemistry and builds on earlier rounds, including $175 million from a Series B in 2023. Investors named include RA Capital Management and Deep Track Capital, along with other participants such as Osage University Partners and BeOne Medicines. Terremoto’s lead programs include TER-2013 for solid tumors with specific genetic alterations and TER-4480 planned for hereditary hemorrhagic telangiectasia, a rare bleeding disorder without approved therapies. The raise arrives as investors concentrate capital into AKT pathway assets that demonstrate differentiation on durability, exposure, or tolerability versus existing contenders.